Deharo P, Bisson A, Herbert J, et al. - Researchers investigated the outcomes of transcatheter aortic valve replacement (TAVR) according to Sapien 3 balloon-expandable (BE) vs Evolut R self-expanding (SE) TAVR technology at a nationwide level in France. The French administrative hospital-discharge database yielded data of a total of 31,113 patients treated with either Sapien 3 BE or Evolut R SE TAVR. They analyzed 20,918 patients after matching on baseline characteristics (10,459 in each group with BE or SE valves). Outcomes from this largest cohort available indicated lower rates of all-cause death, cardiovascular death, rehospitalization for heart failure, and pacemaker implantation after a TAVR procedure in correlation to Sapien 3 BE valves.